News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
46,788 Results
Type
Article (4321)
Company Profile (3)
Press Release (42464)
Multimedia
Podcasts (21)
Webinars (1)
Section
Business (13097)
Career Advice (90)
Deals (2401)
Drug Delivery (11)
Drug Development (6465)
Employer Resources (6)
FDA (1332)
Job Trends (1059)
News (23330)
Policy (2318)
Tag
Academia (128)
Accelerated approval (5)
Adcomms (1)
Allergies (35)
Alliances (3806)
ALS (18)
Alzheimer's disease (63)
Antibody-drug conjugate (ADC) (25)
Approvals (1397)
Artificial intelligence (65)
Autoimmune disease (30)
Automation (2)
Bankruptcy (10)
Best Places to Work (749)
Biosimilars (12)
Biotechnology (1)
Bladder cancer (3)
Brain cancer (8)
Breast cancer (47)
Cancer (435)
Cardiovascular disease (34)
Career advice (72)
Career pathing (1)
CAR-T (18)
CDC (7)
Cell therapy (40)
Cervical cancer (1)
Clinical research (5675)
Collaboration (166)
Compensation (9)
Complete response letters (10)
COVID-19 (356)
CRISPR (10)
C-suite (113)
Cystic fibrosis (10)
Data (667)
Denatured (1)
Depression (4)
Dermatology (12)
Diabetes (58)
Diagnostics (350)
Digital health (6)
Diversity, equity & inclusion (1)
Drug discovery (29)
Drug pricing (25)
Duchenne muscular dystrophy (15)
Earnings (4707)
Editorial (8)
Employer branding (2)
Employer resources (5)
Events (5149)
Executive appointments (103)
FDA (1620)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (2)
Frontotemporal dementia (4)
Funding (160)
Gene editing (21)
Generative AI (6)
Gene therapy (71)
GLP-1 (161)
Government (360)
Grass and pollen (2)
Guidances (50)
Healthcare (908)
HIV (2)
Huntington's disease (3)
IgA nephropathy (1)
Immunology and inflammation (73)
Immuno-oncology (19)
Indications (25)
Infectious disease (404)
Inflammatory bowel disease (26)
Inflation Reduction Act (1)
Influenza (24)
Intellectual property (11)
Interviews (12)
IPO (712)
IRA (4)
Job creations (350)
Job search strategy (71)
JPM (7)
Labor market (3)
Layoffs (64)
Leadership (1)
Legal (440)
Liver cancer (6)
Longevity (2)
Lung cancer (62)
Lymphoma (39)
Machine learning (9)
Management (2)
Manufacturing (85)
MASH (46)
Medical device (770)
Medtech (775)
Mergers & acquisitions (1771)
Metabolic disorders (168)
mRNA (34)
Multiple sclerosis (32)
NASH (4)
Neurodegenerative disease (40)
Neuropsychiatric disorders (9)
Neuroscience (179)
Neurotech (1)
NextGen: Class of 2026 (260)
Non-profit (185)
Now hiring (3)
Obesity (53)
Opinion (35)
Ovarian cancer (13)
Pain (15)
Pancreatic cancer (26)
Parkinson's disease (16)
Patents (24)
Patient recruitment (47)
Peanut (20)
People (4493)
Pharmaceutical (1)
Pharmacy benefit managers (2)
Phase 1 (1515)
Phase 2 (2348)
Phase 3 (2435)
Pipeline (719)
Policy (32)
Postmarket research (258)
Preclinical (587)
Press Release (2)
Prostate cancer (29)
Psychedelics (3)
Radiopharmaceuticals (26)
Rare diseases (110)
Real estate (423)
Recruiting (3)
Regulatory (2029)
Reports (10)
Research institute (141)
Resumes & cover letters (12)
RNA editing (1)
RSV (15)
Schizophrenia (3)
Series A (32)
Series B (29)
Sickle cell disease (9)
Special edition (5)
Spinal muscular atrophy (11)
Startups (301)
Stomach cancer (1)
Supply chain (11)
Tariffs (11)
The Weekly (20)
Vaccines (188)
Venture capital (16)
Weight loss (37)
Women's health (5)
Worklife (1)
Date
Today (10)
Last 7 days (52)
Last 30 days (226)
Last 365 days (2098)
2026 (849)
2025 (2325)
2024 (2363)
2023 (2620)
2022 (5696)
2021 (3863)
2020 (3012)
2019 (2456)
2018 (1940)
2017 (2681)
2016 (2419)
2015 (2801)
2014 (1980)
2013 (1529)
2012 (1622)
2011 (1613)
2010 (1423)
Location
Africa (89)
Arizona (3)
Asia (2397)
Australia (314)
California (608)
Canada (99)
China (122)
Colorado (6)
Connecticut (8)
Delaware (27)
Europe (19689)
Florida (41)
Georgia (16)
Idaho (1)
Illinois (27)
India (8)
Indiana (12)
Japan (29)
Kansas (8)
Louisiana (1)
Maine (1)
Maryland (53)
Massachusetts (466)
Michigan (4)
Minnesota (15)
Missouri (2)
Nebraska (1)
Nevada (1)
New Hampshire (4)
New Jersey (123)
New Mexico (1)
New York (329)
North Carolina (37)
Northern California (418)
Ohio (3)
Oregon (2)
Pennsylvania (86)
Puerto Rico (1)
Rhode Island (1)
South America (108)
South Carolina (8)
Southern California (165)
Tennessee (1)
Texas (143)
United States (2025)
Utah (19)
Virginia (24)
Washington D.C. (2)
Washington State (11)
Wisconsin (3)
46,788 Results for "sanofi france".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Manufacturing
Amgen, Sanofi commit nearly $600M to North American expansions
Sanofi’s investment will support a Canadian site’s efforts to apply AI to drug production, while Amgen has unveiled the second expansion of its Puerto Rico plant in quick succession.
May 6, 2026
·
2 min read
·
Nick Paul Taylor
FDA
Makary’s out at FDA, Sanofi’s priority voucher issues, top exec pay
It’s official: FDA Commissioner Marty Makary is out at the FDA after reports of his ouster emerged late last week; Sanofi is reportedly having challenges with one of the FDA’s new signature programs; and biopharma CEOs’ multimillion-dollar salaries ticked up again this year. Who made the most in 2025?
May 13, 2026
·
1 min read
·
Heather McKenzie
FDA
Sanofi requests removal of Tzield from CNPV program after Høeg gets involved
Acting Center for Drug Evaluation and Research Director Tracy Beth Høeg reportedly disagreed with staff who wanted to approve Sanofi’s type 1 diabetes drug. It’s far from the first time a political appointee has allegedly meddled in a recent FDA decision.
May 7, 2026
·
4 min read
·
Heather McKenzie
Earnings
Sanofi defends Dupixent patents, but execs insist it has nothing to do with CEO change
Sanofi’s interim leadership sought on a Thursday earnings call to quell concerns that its sudden defense of Dupixent’s patents had anything to do with the departure of CEO Paul Hudson.
April 23, 2026
·
3 min read
·
Annalee Armstrong
C-suite
Garijo starts as Sanofi CEO with window to ease reliance on Dupixent
The new CEO has at least five years and a large M&A war chest to position Sanofi for life after the loss of exclusivity on its cornerstone immunology product.
April 28, 2026
·
4 min read
·
Nick Paul Taylor
Drug development
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off
Sanofi has faced questions about the potential of lunsekimig in eczema, with executives calling the clinical trial a “measured risk.”
April 7, 2026
·
2 min read
·
Annalee Armstrong
Immunology and inflammation
Sanofi Keeps Immuno Deals Coming With Kali Bet Worth Potential $1B+
Kali Therapeutics’ T cell engager, for which Sanofi is initially paying $180 million, could potentially be developed for a range of B cell–driven autoimmune disorders.
March 23, 2026
·
2 min read
·
Tristan Manalac
Funding
Backed by Sanofi, Pfizer, Earendil Bags $787M for AI-Driven Biologics Design
Earendil Labs’ AI-centered platform has produced more than 40 programs, including anti-inflammatory assets that have attracted a pair of partnership agreements with Sanofi.
March 23, 2026
·
2 min read
·
Tristan Manalac
Vaccines
Sanofi Suffers Another Sales Dip for ‘Gift to Public Health’ Vaccines
Sanofi’s vaccine sales dipped 2.5% in 2025, with almost all immunization products declining. Nevertheless, CEO Paul Hudson doubled down on his support for vaccine development.
January 29, 2026
·
2 min read
·
Tristan Manalac
Vaccines
JPM26: Sanofi’s CEO Keen To Buy the Dip as Vaccine Rhetoric Impacts Short-Term Sales
Buying vaccine biotech Dynavax was an easy choice for Sanofi despite anti-vaccine moves by the Trump administration.
January 14, 2026
·
3 min read
·
Annalee Armstrong
1 of 4,679
Next
